Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer

BACKGROUND: Abiraterone acetate (AA) is the prodrug of abiraterone, which inhibits CYP17A1 and testosterone synthesis and prolongs the survival of patients with metastatic castration-resistant prostate cancer (mCRPC). AA plus prednisone (AA + P) is approved for the treatment of patients with mCRPC....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Urol
Main Authors: Fizazi, Karim, Chi, Kim N., de Bono, Johann S., Gomella, Leonard G., Miller, Kurt, Rathkopf, Dana E., Ryan, Charles J., Scher, Howard I., Shore, Neal D., De Porre, Peter, Londhe, Anil, McGowan, Tracy, Pelhivanov, Nonko, Charnas, Robert, Todd, Mary B., Montgomery, Bruce
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570464/
https://ncbi.nlm.nih.gov/pubmed/26965562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.02.035
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados